3rdPartyFeeds News

: Pfizer’s $43 billion bid for Seagen aims to broaden company’s cancer portfolio

Pfizer plans to pay $229 per share in cash for Seagen, whose stock soared more than 15% in trading on Monday afternoon. Pfizer’s shares gained about 1.7%. Read More...

Pfizer’s PFE proposed acquisition of Seagen SGEN, which develops cancer treatments, for $43 billion indicates that the legacy drugmaker is focused on shoring up its oncology business.

Pfizer said Monday it plans to pay $229 per share in cash for Seagen, whose stock soared more than 15% in trading on Monday afternoon. Pfizer’s shares gained about 1.7%.

“[Seagen’s]…

Read More

Add Comment

Click here to post a comment